Endocrine Abstracts

Objective: The prevalence of primary aldosteronism (PA) occures in approximately 5–10% of patients with hypertension. Aldosterone induces fluid retention and a variety of angiopathy. We investigated the course of hypertension and renal function in the post-treatment period.

Methods: Nine patients with PA were performed adrenalectomy and 21 patients were administered medications including mineralocorticoid receptor brocker. Blood pressure, serum potassium, aldosterone, plasma rennin-activity (PRA), the aldosterone/renin ratio (ARR), and renal function were evaluated between pre- and post-treatment.

Results: Systolic blood pressure and ARR were significantly decreased and serum potassium level was significantly increased in both groups. However, eGFR was decreased 1 year after treatment in both groups. Drug utilization for hypertension was increased in the group of medication, whereas was not in the group of operation.

Conclusion: Blood pressure was significantly decreased both the treatment of operation and medication. However, renal function was decreased despite the treatment of operation or medication. Fluid retention and vascular distance caused by hypersecretion of aldosterone induced hypertension. The treatments would induce efferent arteriole dilatation and decreased renal blood flow by reduction of blood pressure. The renal dysfunction is considered to be influenced by renal blood flow. Careful long-term follow-up was necessary, because differences of the PA duration and the treatment may affect the course of renal function.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.